AUG 14, 2018 11:40 PM PDT

Using Arsenic to Enhance Cancer Therapies Beyond Leukemia

Arsenic is anecdotally known to many as a poison, but it has historically been a potent chemotherapy agent.  Chemotherapies are basically controlled poisons; it is not so far-fetched to think of arsenic in these terms.  Originally used to treat leukemia in the nineteenth century, known as Fowler’s solution, arsenic continues to be investigated and used in conjunction with all-trans retinoic acid (ATRA) for the treatment and cure of Acute Promyelocytic Leukemia (APL).  Specifically, arsenic trioxide (ATO) is the active component needed to promote the anti-leukemic process in the body.  ATO acts on APL by destroying the main fusion protein called PML-RARα which is the disease driving genetic change causing the arrest of myelocytic cell differentiation.  Myelocytic cells need retinoic acid, or vitamin A, to continue developing into mature neutrophils which is why ATRA was used in the first place. 

A recent study published in Nature Communications outlines how ATO and ATRA together target an oncogenic signaling regulator called Pin1.  Pin1 activity is documented in multiple cancers besides leukemia including breast and liver solid tumors.  ATO has been found to degrade Pin1 and ATRA controls the cell’s ability to take up ATO when it is in the body.    

This is an emerging area of research because solid tumors are challenging to target; tumors are often found to utilize multiple activation pathways to remain viable and support their rapid growth.  Blocking one pathway may not work but finding the target that drives a multitude of signaling mechanisms, like in the case of Pin1, provides promise.  ATO and ATRA together have been proven safe at clinical doses and inhibited triple negative breast cancer cells as well as other tumor initiating cells in animal models. 

In vivo studies and clinically relevant data have demonstrated the viability and efficacy of using arsenic in conjunction with other therapeutic agents, like in the case of ATO-ATRA and APL.  Because this combination was found to impede further tumor growth via tumor initiating cells, the tumor’s normal renewal and progression process is disrupted.  In fact, the authors found that Pin1 is “highly enriched” in breast tumor initiating cells and propose further study on whether Pin1 inhibitor drugs could target these specific breast tumor cells.

Sources: Nature Communications, Pathology Outlines, Nature Medicine, Journals of Hematology & Oncology,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 17, 2019
Drug Discovery & Development
NOV 17, 2019
Aspirin Usage Improves Liver Function After Embolization Treatment
Aspirin usage has been under scrutiny in recent research. But now, studies are bringing aspirin therapy in renewed light with its association in improving ...
NOV 17, 2019
Cancer
NOV 17, 2019
Bias against unmarried cancer patients
A new study published in The New England Journal of Medicine examines the biases behind the cancer treatments that doctors prescribe, coming to the conclus...
NOV 17, 2019
Cancer
NOV 17, 2019
The golden future of cancer treatment
A study published recently in Chemistry -- A European Journal features research on the golden cancer treatments of the future – literally. Current me...
NOV 17, 2019
Cancer
NOV 17, 2019
New treatment to reduce hair loss during chemotherapy
Chemotherapy-induced hair loss is debatably one of the more devastating psychologically-visible difficulties of cancer. However, new research from the labo...
NOV 17, 2019
Cancer
NOV 17, 2019
Detecting breast cancer in men
New research published recently in the journal Radiology suggests the need for improved mammography screening for men who are at high risk for breast cance...
NOV 17, 2019
Cancer
NOV 17, 2019
Looking at the bigger picture: immune cells in a human body
While laboratory-conducted research has allowed for countless scientific advancements over the years, it may not come as a surprise that studying cells in ...
Loading Comments...